|Synonyms||MLE-4901; AZD-4901; AZD-2624; AZ-12472520|
|Chemical and physical data|
|Molar mass||459.564 g/mol g·mol−1|
|3D model (JSmol)|
Pavinetant (INN, USAN; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS). It was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness. In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits.
- Malherbe P, Ballard TM, Ratni H (2011). "Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010)". Expert Opin Ther Pat. 21 (5): 637–55. doi:10.1517/13543776.2011.568482. PMID 21417773.
- Sassarini J, Anderson RA (2017). "New pathways in the treatment for menopausal hot flushes". Lancet. doi:10.1016/S0140-6736(17)30886-3. PMID 28385351.
- Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ (2014). "The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study". J Clin Psychopharmacol. 34 (2): 199–204. doi:10.1097/JCP.0000000000000071. PMID 24525659.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|